RxDoctor Payments Data

Samuel Anim, MD

Pediatric Hematology-Oncology · Fargo, NDNPI 1053514844

Payments from drug & device makers

$38,608in general payments, 2019–2025

Across 19 payments — averaging $2031.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Agios Pharmaceuticals, Inc.$37K
  • Novartis$1K
  • Chiesi USA, Inc.$125
  • Novo Nordisk$125
  • Pfizer$42
  • Shire North American Group Inc$17
  • plus $30 from 2 others
$1,100in research payments, 2019–2025

Across 7 payments — averaging $157.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

What the payments were for

  • Travel & lodging$99958%
  • Food & beverage$72542%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric hematology-oncology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,663
Medicare patients
19
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor13$158,768
Deferasirox23$28,852
EliquisApixaban32$17,571
OxycontinOxycodone Hcl18$15,193
Oxycodone Hcl276$3,253
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$2,059
Hydromorphone Hcl89$1,329
Hydroxyurea49$988
Methadone Hcl51$706
Naloxone Hcl15$699
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$524
Cyclobenzaprine Hcl50$210
Naproxen24$147
Gabapentin12$144
Tizanidine Hcl25$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$17,57132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric hematology-oncology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other pediatric hematology-oncology in Fargo

Where these figures come from

Is this you, or does something look wrong? →